标准治疗中阿基仑赛用于复发或难治性大B细胞淋巴瘤:美国淋巴瘤CAR-T联盟结果
该回顾性研究纳入17家美国机构截至2018年9月30日接受白细胞分离术的复发/难治性大B细胞淋巴瘤患者,298例中275例(92%)接受了阿基仑赛治疗。输注患者最佳总缓解率和完全缓解率分别为82%(95%CI 77%-86%)和64%(95%CI 58%-69%),≥3级细胞因子释放综合征和神经毒性发生率分别为7%和31%。
要点
- 输注患者最佳总缓解率82%,完全缓解率64%。
- ≥3级细胞因子释放综合征7%,≥3级神经毒性31%。
- 中位随访12.9个月,中位无进展生存期8.3个月,中位总生存期未达到。
核心结论
- 在复发/难治性大B细胞淋巴瘤的标准治疗中,阿基仑赛的安全性和疗效与注册研究ZUMA-1相当。
研究设计与样本
- 回顾性研究,收集截至2018年9月30日在17家美国机构接受白细胞分离术、意图接受标准治疗阿基仑赛的复发/难治性大B细胞淋巴瘤患者数据。
- 共298例患者接受白细胞分离术,其中275例(92%)接受了阿基仑赛治疗。
- 毒性按各机构指南分级和管理,缓解按Lugano 2014分类评估。
主要发现
- 与注册研究ZUMA-1相比,本标准治疗研究中129例患者(43%)因白细胞分离术时的合并症不符合ZUMA-1入选标准。
- 接受阿基仑赛治疗的患者中,≥3级细胞因子释放综合征发生率为7%,≥3级神经毒性发生率为31%。
- 非复发死亡率为4.4%。
- 输注患者最佳总缓解率为82%(95%CI 77%-86%),完全缓解率为64%(95%CI 58%-69%)。
- 自CAR-T细胞输注起中位随访12.9个月,中位无进展生存期为8.3个月(95%CI 6.0-15.1个月),中位总生存期未达到。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Axicabtagene ciloleucel (axi-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory large B-cell lymphoma (LBCL) on the basis of the single-arm phase II ZUMA-1 trial, which showed best overall and complete response rates in infused patients of 83% and 58%, respectively. We report clinical outcomes with axi-cel in the standard-of-care (SOC) setting for the approved indication. PATIENTS AND METHODS: Data were collected retrospectively from all patients with relapsed/refractory LBCL who underwent leukapheresis as of September 30, 2018, at 17 US institutions with the intent to receive SOC axi-cel. Toxicities were graded and managed according to each institution's guidelines. Responses were assessed as per Lugano 2014 classification. RESULTS: Of 298 patients who underwent leukapheresis, 275 (92%) received axi-cel therapy. Compared with the registrational ZUMA-1 trial, 129 patients (43%) in this SOC study would not have met ZUMA-1 eligibility criteria because of comorbidities at the time of leukapheresis. Among the axi-cel-treated patients, grade ≥ 3 cytokine release syndrome and neurotoxicity occurred in 7% and 31%, respectively. Nonrelapse mortality was 4.4%. Best overall and complete response rates in infused patients were 82% (95% CI, 77% to 86%) and 64% (95% CI, 58% to 69%), respectively. At a median follow-up of 12.9 months from the time of CAR T-cell infusion, median progression-free survival was 8.3 months (95% CI, 6.0 to15.1 months), and median overall survival was not reached. Patients with poor Eastern Cooperative Oncology Group performance status of 2-4 and elevated lactate dehydrogenase had shorter progression-free and overall survival on univariable and multivariable analysis. CONCLUSION: The safety and efficacy of axi-cel in the SOC setting in patients with relapsed/refractory LBCL was comparable to the registrational ZUMA-1 trial.
引用
- Nastoupil LJ, Jain MD, Feng L, et al. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. J Clin Oncol. 2020. PMID: 32401634. doi:10.1200/JCO.19.02104
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。